XML 30 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Basis of Presentation and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated statements of cash flows that sum to the total of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):

 

 

 

Nine Months Ended September 30, 2025

 

 

Nine Months Ended September 30, 2024

 

 

 

Beginning of
period

 

 

End of
period

 

 

Beginning of
period

 

 

End of
period

 

Cash and cash equivalents

 

$

319,589

 

 

$

257,996

 

 

$

188,657

 

 

$

155,149

 

Restricted cash

 

 

8,770

 

 

 

9,471

 

 

 

5,770

 

 

 

8,770

 

Total cash, cash equivalents and restricted cash shown in
   the unaudited condensed consolidated statements of cash flows

 

$

328,359

 

 

$

267,467

 

 

$

194,427

 

 

$

163,919

 

Schedule of revenue consist of product sales to customers

The Company operates in one business segment. Results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues consist of net product sales to customers, all of which are sales in North America. Revenues by product are as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

NUPLAZID

 

$

177,530

 

 

$

159,186

 

 

$

505,730

 

 

$

446,518

 

DAYBUE

 

 

101,103

 

 

 

91,215

 

 

 

281,786

 

 

 

251,677

 

   Product sales, net

 

$

278,633

 

 

$

250,401

 

 

$

787,516

 

 

$

698,195